PBMs agree to show TrumpRx pricing
Pharmacy benefit managers have agreed to display drug prices from the TrumpRx program. The move is part of broader biotech news including Bristol's Zenbexus approval and Novartis' patent win.
Related stories
Ivonescimab's progression-free survival benefit fades over time · Cancer research
Debate over optimal cancer drug dosing intensifies · Cancer research
Weekly Health News: Presidential Weight, Fauci Defense, and More · Public health
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “STAT+: PBMs agree to display TrumpRx drug prices.” Browse more stories.